ITM Isotope Technologies has provided more detail on how its lead radiotherapy bested the standard of care in a recent phase 3 study while revealing that the candidate was unable to prove a ...

ITM opens new production facility_ITM COO Dr. Mark Harfensteller_ITM Chairman of the Board Udo Vetter_Minister of State Dr. Florian Herrmann_ITM CEO Steffen Schuster_Mayor Neufahrn Franz Heilmeier ITM ...

ITM Isotope Technologies Munich and Swiss-based Debiopharm have announced the imaging of the first subject in a new study arm (Part D) of the Phase I/II trial assessing peptide-based theranostic pair ...

ITM-11 significantly improved progression-free survival over everolimus in GEP-NETs patients, marking a first for targeted radiopharmaceutical therapy in a phase 3 trial. The COMPETE trial included ...

GARCHING & MUNICH, Germany--(BUSINESS WIRE)--ITM AG, a leading radiopharmaceutical company, announced today the close of a private equity financing round from existing and new investors, related and ...

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced that the US Food and Drug Administration (FDA) has granted the company Fast Track designation for ITM ...

Garching / Munich, Germany, May 27, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a debt financing agreement for up to USD 262.5 ...

GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc.

GARCHING & MUNICH, Germany--(BUSINESS WIRE)--ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as ...

Isotope Technologies Munich SE (ITM) raised €188 million ($204 million) in a funding round that will largely be used to advance and expand the company’s radiopharmaceutical pipeline. The funds, which ...